Insight, China's Pharmaceutical Industry

Yangzi State‑Owned Investment Group & Perennial Real Estate Join Forces to Build Jiangsu’s First Foreign‑Owned General Hospital

Yangzi State‑Owned Investment Group (JSIG) and Singapore‑based Perennial Real Estate Holdings Limited (Perennial Group) signed...

Company Drug

Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina

Fineline Cube Nov 3, 2025

Shanghai CirCode Biomed Co. Ltd. announced that its self‑developed circular RNA (circRNA) therapeutic HM2002 has received...

Company Deals Drug

TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration

Fineline Cube Nov 3, 2025

TransThera Sciences (Nanjing) Inc. (HKG: 2617) announced today that it has entered into a royalty‑bearing patent‑assignment...

Company Deals

Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy

Fineline Cube Nov 3, 2025

Betta Pharmaceuticals Co., Ltd. (SHE: 300558) announced today the signing of a Strategic Cooperation Framework...

Company

AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges

Fineline Cube Nov 3, 2025

U.S. biopharma leader AbbVie Inc. (NYSE: ABBV) released its third‑quarter fiscal‑2025 results. Net revenues rose...

Company

Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating‑Profit Surge in H1 FY2025

Fineline Cube Nov 3, 2025

Astellas Pharma Inc. (TYO: 4503) released its consolidated six‑month results for fiscal year 2025 (1 Apr 2025 – 30 Sep 2025). The...

Policy / Regulatory

FDA Issues Draft Guidance to Accelerate Biosimilar Development and Cut Costs

Fineline Cube Nov 3, 2025

The U.S. Food and Drug Administration (FDA) released a draft guidance titled “Scientific Considerations in...

Company Drug

Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC

Fineline Cube Nov 3, 2025

Shanghai Simnova Biotech Co., Ltd. announced that its self‑developed anti‑DLL3 chimeric antigen receptor T‑cell (CAR‑T)...

Company Drug

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer

Fineline Cube Nov 3, 2025

Akeso Inc. (HKG: 9926) announced that its proprietary bispecific antibody ivonescimab (AK112) has been granted...

Company Deals

CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China

Fineline Cube Nov 3, 2025

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a core subsidiary of Sino Biopharmaceutical Limited...

Policy / Regulatory

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns

Fineline Cube Nov 3, 2025

The U.S. Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) confirmed that...

Company Deals

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Fineline Cube Nov 3, 2025

Lepu (Beijing) Medical Technology Co., Ltd. (SHE: 300003) announced that its wholly‑owned subsidiary Shanghai Minwei...

Company Drug

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma

Fineline Cube Oct 31, 2025

Transcenta Holding Limited (HKG: 6628) announced that its partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) has...

Company Deals Drug

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy

Fineline Cube Oct 31, 2025

Boehringer Ingelheim announced a licensing deal to acquire exclusive worldwide rights to a promising first‑in‑class...

Company Deals

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development

Fineline Cube Oct 31, 2025

China‑based Chengdu Maxvax Biotechnology Co., Ltd. announced the successful completion of its Series D funding round,...

Company

BMS Reports Q3 2025 Results: 2% Global Revenue Growth

Fineline Cube Oct 31, 2025

US‑based Bristol-Myers Squibb (BMS; NYSE: BMY) delivered its third‑quarter 2025 earnings, showing a modest 2%...

Company

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%

Fineline Cube Oct 31, 2025

Gilead Sciences Inc. (NASDAQ: GILD) today announced its third‑quarter 2025 financial results. Total revenues reached...

Company

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Fineline Cube Oct 31, 2025

Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third‑quarter 2025 financial results,...

Company

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Fineline Cube Oct 31, 2025

Eli Lilly & Co. (NYSE: LLY) today announced that its third‑quarter 2025 financial results exceeded...

Company Drug

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

Fineline Cube Oct 31, 2025

Jiangsu Jebel Pharma Co., Ltd. (SHA: 688566) today announced that its novel antidepressant JJH201501, developed...

Insight, China's Pharmaceutical Industry

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

InduPro Secures Sanofi Investment and First Negotiation Rights on PD-1 Agonist Program

Brii Biosciences Taps OpenBench AI Platform to Accelerate Drug Discovery

GSK Terminates Ideaya Synthetic Lethality Partnership, Returns Two Clinical Programs

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment

Yangzi State‑Owned Investment Group & Perennial Real Estate Join Forces to Build Jiangsu’s First Foreign‑Owned General Hospital

Shanghai CirCode’s HM2002 Gains China NMPA Approval for Refractory Angina

TransThera Sciences and Neurocrine Biosciences Ink $881.5 M NLRP3 Collaboration

Betta Pharma Secures Exclusive Greater‑China Rights to Gensciences’ Long‑Acting Factor VIII Therapy

AbbVie Posts 8.4% Revenue Gain in Q3 2025, EPS Slumps on IPR&D Charges

Astellas Pharma Posts 10% Revenue Rise and 54% Core Operating‑Profit Surge in H1 FY2025

FDA Issues Draft Guidance to Accelerate Biosimilar Development and Cut Costs

Simnova’s DLL3‑Targeted CAR‑T (SNC115) Wins First‑In‑China Clinical‑Trial Approval for Relapsed SCLC

Akeso’s ivonescimab (AK112) Receives Fourth Breakthrough Therapy Designation in China for Triple‑Negative Breast Cancer

CTTQ Deepens Partnership with Shionogi to Accelerate Naldemedine Launch in China

FDA CDER Director George Tidmarsh Placed on Leave Amid Probe Over Drug‑Approval Program Concerns

Lepu’s Minwei Licenses MWN105 Injection to Denmark’s Sidera Bio, Up to $1.01 B in Milestones

Transcenta Holding Announces Positive Phase III Results for Inhibrx’s Ozekibart in Advanced Chondrosarcoma

Boehringer Ingelheim Licenses Pre‑Clinical Small‑Molecule Program from Kyowa Kirin for Autoimmune Therapy

Chengdu Maxvax Secures Series D Financing at Over RMB 400 Million to Accelerate Shingles and RSV Vaccine Development

BMS Reports Q3 2025 Results: 2% Global Revenue Growth

Gilead Sciences Reports 3% YoY Q3 2025 Revenue Growth, HIV Sales Up 4%

MSD Reports 3% YoY Q3 2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio‑Pulmonary Portfolio

Eli Lilly Reports 54% YoY Revenue Surge in Q3 2025, Raises Full‑Year Guidance to $63 B

Jebel Pharma Reports Positive Phase III Results for JJH201501 Antidepressant

You Missed

Peijia Medical Wins NMPA Approval for TaurusTrio TAV, First Transfemoral System for Aortic Regurgitation

Everest Medicines Licenses Lerodalcibep PCSK9 Inhibitor in $339M Greater China Deal

Lilly’s Retatrutide Achieves 28.7% Weight Loss in Phase 3 Obesity-Osteoarthritis Trial

Joincare’s Pixavir Marboxil Wins NMPA Approval as First Single‑Dose Flu Treatment